![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SYPL2 |
Gene summary for SYPL2 |
![]() |
Gene information | Species | Human | Gene symbol | SYPL2 | Gene ID | 284612 |
Gene name | synaptophysin like 2 | |
Gene Alias | MG29 | |
Cytomap | 1p13.3 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | Q5VXT5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284612 | SYPL2 | S014 | Human | Liver | HCC | 2.32e-03 | 2.18e-01 | 0.2254 |
284612 | SYPL2 | S015 | Human | Liver | HCC | 4.55e-03 | 2.89e-01 | 0.2375 |
284612 | SYPL2 | S016 | Human | Liver | HCC | 4.85e-06 | 2.79e-01 | 0.2243 |
284612 | SYPL2 | S027 | Human | Liver | HCC | 4.17e-12 | 6.43e-01 | 0.2446 |
284612 | SYPL2 | S028 | Human | Liver | HCC | 2.45e-21 | 6.89e-01 | 0.2503 |
284612 | SYPL2 | S029 | Human | Liver | HCC | 3.00e-19 | 7.39e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002176222 | Liver | HCC | substantia nigra development | 33/7958 | 44/18723 | 1.21e-05 | 1.38e-04 | 33 |
GO:003090121 | Liver | HCC | midbrain development | 54/7958 | 90/18723 | 6.04e-04 | 3.79e-03 | 54 |
GO:004885722 | Liver | HCC | neural nucleus development | 38/7958 | 64/18723 | 4.78e-03 | 2.02e-02 | 38 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SYPL2 | SNV | Missense_Mutation | novel | c.215A>G | p.Asp72Gly | p.D72G | Q5VXT5 | protein_coding | tolerated(0.09) | benign(0.315) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SYPL2 | SNV | Missense_Mutation | rs775749958 | c.529G>A | p.Asp177Asn | p.D177N | Q5VXT5 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD |
SYPL2 | insertion | Frame_Shift_Ins | novel | c.327_328insTTCCATACTCCTA | p.Asp110PhefsTer160 | p.D110Ffs*160 | Q5VXT5 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
SYPL2 | insertion | Frame_Shift_Ins | novel | c.328_329insTTCAGGTCTCCTTTCACTCCATAATGCTA | p.Asp110ValfsTer20 | p.D110Vfs*20 | Q5VXT5 | protein_coding | TCGA-A8-A07J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
SYPL2 | deletion | Frame_Shift_Del | novel | c.328delG | p.Asp110ThrfsTer10 | p.D110Tfs*10 | Q5VXT5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
SYPL2 | SNV | Missense_Mutation | c.810G>T | p.Glu270Asp | p.E270D | Q5VXT5 | protein_coding | tolerated(0.71) | benign(0.003) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SYPL2 | SNV | Missense_Mutation | c.666N>A | p.Asn222Lys | p.N222K | Q5VXT5 | protein_coding | deleterious(0) | benign(0.067) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
SYPL2 | SNV | Missense_Mutation | c.367N>G | p.Ile123Val | p.I123V | Q5VXT5 | protein_coding | tolerated(1) | benign(0.005) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SYPL2 | SNV | Missense_Mutation | c.85N>T | p.Arg29Trp | p.R29W | Q5VXT5 | protein_coding | deleterious(0.01) | benign(0.17) | TCGA-CM-5860-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | SD | |
SYPL2 | SNV | Missense_Mutation | rs192895878 | c.193N>T | p.Arg65Cys | p.R65C | Q5VXT5 | protein_coding | deleterious(0.02) | possibly_damaging(0.659) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |